Full text pdf availible: http://clincancerres.aacrjournals.org/content/early/2016/10/21/1078-0432.CCR-16-0569.full-text.pdf The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models